{"id":33175,"date":"2025-05-12T14:58:45","date_gmt":"2025-05-12T06:58:45","guid":{"rendered":"https:\/\/flcube.com\/?p=33175"},"modified":"2025-05-12T14:58:46","modified_gmt":"2025-05-12T06:58:46","slug":"ucb-gets-japanese-approval-for-new-administration-routes-of-rystiggo-in-gmg","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33175","title":{"rendered":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG"},"content":{"rendered":"\n

Belgium-based biopharma UCB (EBR: UCB<\/a>)\u00a0announced that it has received marketing approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.<\/p>\n\n\n\n

Rystiggo’s Unique Position<\/strong>
Rystiggo stands as the world’s first and only neonatal Fc receptor (FcRn) antagonist approved for both AChR-positive and MuSK-positive gMG. This innovation marks a significant advancement in the treatment landscape for patients living with this rare condition.<\/p>\n\n\n\n

UCB Japan’s Home Delivery Service<\/strong>
In line with the approval, UCB Japan will launch a home delivery service for Rystiggo. This service will include portable syringe pumps and is part of the ONWARD program. ONWARD is a global patient support initiative by UCB designed to assist individuals living with rare diseases like gMG. The program offers features such as symptom tracking, support from dedicated Care Coordinators for each patient, and access to 24\/7 online tools.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan’s Pharmaceuticals and…<\/p>\n","protected":false},"author":1,"featured_media":33176,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2015,15,24],"class_list":["post-33175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ebr-ucb","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"\nUCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33175\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG\" \/>\n<meta property=\"og:description\" content=\"Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33175\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-12T06:58:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T06:58:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG\",\"datePublished\":\"2025-05-12T06:58:45+00:00\",\"dateModified\":\"2025-05-12T06:58:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175\"},\"wordCount\":192,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1211.webp\",\"keywords\":[\"EBR: UCB\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33175#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33175\",\"name\":\"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1211.webp\",\"datePublished\":\"2025-05-12T06:58:45+00:00\",\"dateModified\":\"2025-05-12T06:58:46+00:00\",\"description\":\"Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33175\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1211.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1211.webp\",\"width\":1080,\"height\":608,\"caption\":\"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33175#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG - Insight, China's Pharmaceutical Industry","description":"Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33175","og_locale":"en_US","og_type":"article","og_title":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG","og_description":"Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.","og_url":"https:\/\/flcube.com\/?p=33175","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-12T06:58:45+00:00","article_modified_time":"2025-05-12T06:58:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33175#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33175"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG","datePublished":"2025-05-12T06:58:45+00:00","dateModified":"2025-05-12T06:58:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33175"},"wordCount":192,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33175#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp","keywords":["EBR: UCB","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33175#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33175","url":"https:\/\/flcube.com\/?p=33175","name":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33175#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33175#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp","datePublished":"2025-05-12T06:58:45+00:00","dateModified":"2025-05-12T06:58:46+00:00","description":"Belgium-based biopharma UCB (EBR: UCB)\u00a0announced that it has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for two new administration routes for its Rystiggo (rozanolixizumab). This approval allows patients with generalized Myasthenia Gravis (gMG) to self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33175#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33175"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33175#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp","width":1080,"height":608,"caption":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33175#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1211.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33175"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33175\/revisions"}],"predecessor-version":[{"id":33177,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33175\/revisions\/33177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33176"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}